BOURSE:IPH

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Retrieved on: 
星期二, 五月 28, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, IPH, IPHA, Euronext Paris, EVP

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below.
  • Participants will include Hervé Brailly, Chief Executive Officer, Sonia Quaratino, Executive Vice President (EVP), Chief Medical Officer, Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations.

Outcome of Innate Pharma’s 2024 Annual General Meeting

Retrieved on: 
星期四, 五月 23, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, IPH, Annual, IPHA, AGM, Euronext Paris, Supervision, Holding company

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23, 2024, in Marseille.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23, 2024, in Marseille.
  • A total of 84 votes were cast out of a total of 36,317,268 shares giving right to 36,798,714 voting rights, representing a quorum of 44.92%.
  • During the meeting, two members of the Supervisory Board who were up for election were re-elected.
  • The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2024 section of the Company’s website.

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Retrieved on: 
星期五, 五月 24, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Relapse, IPH, IPHA, Annual general meeting, CD20, ASCO, Abstract, Society, Euronext Paris, MOZART, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.
  • Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial
    Abstract Title: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
    Abstract Title: Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison to a CD20-targeting T Cell Engager
    Abstract Title: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.

Innate Pharma: Clarification Regarding SAR443579 Designation

Retrieved on: 
星期二, 五月 21, 2024
Oncology, Health, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, Sanofi, IPH, Congress, IPHA, Fast track (FDA), Euronext Paris

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.
  • This is an error.
  • The molecule has US FDA Fast Track Designation, as communicated before in June 2023.

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Retrieved on: 
星期三, 五月 15, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lymphoma, Sanofi, Patient, Relapse, IPH, Safety, Congress, IPHA, EHA, Abstract, CD20, Bone marrow, CD123, Society, High, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
  • Two abstracts are related to SAR443579 (IPH6101), an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi and currently being evaluated as a monotherapy in a Sanofi-sponsored Phase 1/2 clinical trial for the treatment of blood cancers with high unmet needs.
  • Two abstracts are related to IPH6501, Innate’s second generation ANKET® for the treatment of relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, currently in Phase 1/2 clinical trial.
  • “We’re pleased to see a continued momentum around our ANKET® platform assets, SAR443579 and IPH6501,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Retrieved on: 
星期二, 五月 14, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, EV, Drug, Relapse, PDX, MF, FDA, Form, CD20, Carcinoma, Amyloidosis, Euronext Paris, Acute myeloid leukemia, Randomized controlled trial, B-ALL, NK, AACR, Telephone, ADC, Neoplasm, PD-1, ATM, NHL, CRT, Acute lymphoblastic leukemia, GEMOX, Food, NSCLC, EVP, ADS, IPHA, Cancer, ASCO, Poster, BCMA, Oxaliplatin, AstraZeneca, Takeda, Bone marrow, IPH, Lung cancer, Prospectus, PTCL, Spacecraft, CD123, Abstract, Webcast, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.
  • Top-line results in MF patients will be presented at the ASCO Annual Meeting 2024 being held May 31 – June 4 in Chicago.
  • Cash, cash equivalents and financial assets of the Company amounted to €113.9 million as of March 31, 2024.
  • Cash, cash equivalents and financial assets as of March 31, 2024 do not include the €4.0 million payment to be received from Sanofi.

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, IPHA, EDT, Telephone, IPH, Euronext Paris

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.
  • Participants during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I9730892
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Retrieved on: 
星期一, 四月 15, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Safety, Hematology, IPHA, Research, AML, IPH, Euronext Paris, Fast track (FDA), Acute lymphoblastic leukemia, Patient, Society, Bone marrow, Syndrome, Acute myeloid leukemia, Clinical trial, Pharmaceutical industry

SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi.

Key Points: 
  • SAR443579 is an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi.
  • SAR443579 received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
  • “The progression of SAR443579 to the Phase 2 expansion part of the clinical trial in blood cancers is another step in bringing this innovative NK cell engager to patients,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.
  • “SAR443579 has shown promising clinical efficacy in the dose escalation of the Phase 1/2 in R/R AML patients, and we look forward to the dose expansion part of the study."

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Retrieved on: 
星期一, 四月 15, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Annual, IPHA, IPH, AGM, Euronext Paris, Code, Security (finance)

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.
  • The Notice of Meeting of this AGM was published on April 15, 2024 in the French legal bulletin.
  • The Annual General Meeting will also be broadcasted live and available at the following link: https://app.livestorm.co/p/6ae4e3e6-227c-465b-a057-88d52b2209a1
    A guided tour of the Company's laboratories is organized on the same day at 9:30 a.m. CEST for shareholders.
  • Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers.

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Retrieved on: 
星期三, 四月 10, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Drug, Carcinoma, IPHA, Doctor of Philosophy, PDX, IPH, Euronext Paris, EV, ADC, DVM, Patient, Therapeutic index, AACR, Cancer, Vaccine

In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.

Key Points: 
  • In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models.
  • Importantly, IPH45 shows stronger activity than EV, in multiple urothelial carcinoma PDX (patient-derived xenografted) mice models, across Nectin-4high and Nectin-4low expression levels.
  • “IPH45 is a novel and differentiated Nectin-4 ADC with preclinical efficacy in tumor types with various expression levels of Nectin-4.
  • Its exatecan payload allow for higher bystander-effect and a broader therapeutic index than MMAE-ADCs," commented Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.